Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.
The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.
One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.
Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.
Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.
For more information, please visit their website at www.ternspharma.com.
Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer and the departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be leaving the company to pursue other opportunities. Mr. Harris will oversee various operations, and key executives will now report directly to the CEO. The company expressed gratitude to Dr. Quirk for her contributions and confidence in the leadership team's ability to advance their pipeline. Mr. Harris brings over 25 years of experience in drug development and is optimistic about Terns' future.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in The Citizens JMP Life Sciences Conference 2024. Senior management will join a fireside chat to discuss the company's small-molecule product candidates for serious diseases like oncology and obesity. The event will be live webcasted on May 14, 2024, at 1:30 p.m. ET, with a replay available for 30 days.
Terns Pharmaceuticals, Inc. announced the granting of an equity inducement award to Melita Sun Jung, the new Chief Business Officer, under the terms of the Inducement Plan. The award includes an option to purchase 475,000 shares of Terns common stock at an exercise price of $5.08 per share, with a 10-year term and vesting over four years.
Terns Pharmaceuticals, a biopharmaceutical company, announces positive data from a Phase 1 study of TERN-701, a potential BCR-ABL inhibitor for CML treatment, showing no food effect on dosing. The ongoing study in healthy volunteers displayed promising results, supporting once-daily dosing with or without food. The company aims to differentiate TERN-701 from the current standard, asciminib, by offering more convenient dosing options. Phase 1 CARDINAL trial is ongoing, with interim data expected in late 2024.